To view this email as a web page, click here.
 
Effects of female libido drug unknown, advocacy group warns
A women’s health organization is concerned about the safety and effectiveness of bremelanotide (Vyleesi) after FDA approved it to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
Read more
 
Top 4 drugs in the pipeline
A new report from OptumRx reveals the top 4 drugs in development for the second quarter of 2019.
Read more
 
Watching the drug pipeline
From our sister brand Managed Healthcare Executive: With a record number of innovative drugs queued for FDA approval, managed healthcare executives have an eye toward innovative new products that tackle difficult conditions.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.